N-succinimidyl-3-(4-methoxyphenyl)propionate | 131450-45-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-succinimidyl-3-(4-methoxyphenyl)propionate
• 英文别名: 1-<3-(4-methoxyphenyl)-1-oxopropoxy>-2,5-pyrrolidinedione；N-succinimidyl-3-(4-hydroxyphenyl)propanoate；3-(4-Methoxyphenyl)propionic acid N-hydroxysuccinimide ester；3-(4-Methoxy-phenyl)-propionic acid 2,5-dioxo-pyrrolidin-1-yl ester；(2,5-dioxopyrrolidin-1-yl) 3-(4-methoxyphenyl)propanoate
• CAS: 131450-45-8
• 化学式: C₁₄H₁₅NO₅
• 分子量: 277.277
• InChiKey: ZBTWSFHDZGKKEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  422.7±47.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-succinimidyl-3-(4-methoxyphenyl)propionate 在 potassium hydroxide 作用下， 生成 3-[(4-methoxyphenyl)ethyl]-1,2,4-triazole-5-thione
  参考文献：
  名称：

  设计和合成一些噻唑三唑基酯作为消炎镇痛药

  摘要：

  为了开发具有降低的致溃疡风险的有效的止痛/抗炎化合物，合成了一系列噻唑三唑基羧酸酯和乙酸酯，并通过光谱和元素分析对其进行了表征。通过角叉菜胶诱导的爪水肿模型筛选所有合成的化合物在小鼠体内的抗炎活性。还通过乙酸诱导的扭体试验评估了爪水肿减少20％的化合物的镇痛活性，并通过测定胃中的脂质过氧化水平来评估其胃溃疡的风险。在测试的化合物中，化合物1，4，6，7，8，图1A，2A，3A，4a，7a，2b和8b在任何测量间隔的不同剂量下均显示出中等至良好的抗炎活性。在镇痛活性测试中，化合物7a，2b和8b是该系列中最活泼的。此外，化合物1，4，和8被认为是在胃安全关于自由基的产生的。

  DOI：

  10.1007/s00044-010-9508-x
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 3-(4-甲氧基苯基)丙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 以86%的产率得到N-succinimidyl-3-(4-methoxyphenyl)propionate
  参考文献：
  名称：

  药物的分解反应出乎意料地简单：琥珀酰亚胺酯的金属介导的Hunsdiecker反应？

  摘要：

  一系列双阳离子organoiridium配合物的[Cp *铱（芳烃）] 2+，（4，5和6）已经被制备为其中π键合的苯基环被附接到由琥珀酰亚胺基酯，从而形成封端的博尔顿的烷基链-用于蛋白质标记的亨特试剂。在溶液中，苄基衍生物4易于分解。琥珀酰亚胺部分的损失，随后导致的[Cp脱羧*的Ir（η-MeOC 6 H ^ 4 Me）中] [BF 4 ] 2（7）。该产物通过光谱和X射线晶体学表征。化合物7结晶在空间群P2 1 /一个与一个= 13.567（5），b = 17.664（1）埃，c ^ = 9.044（5），β= 90.15°，V = 2167A 3和Z = 4，一种理为此，令人惊讶的是，容易分解会引起铱对中间苄基的稳定作用。

  DOI：

  10.1016/0022-328x(94)24772-b

文献信息

• Derivatives of tetrapeptides as CCK agonists
  申请人：Abbott Laboratories

  公开号：US05270302A1

  公开（公告）日：1993-12-14

  Selective and potent Type-A CCK receptor agonists of formula (I): X--Y--Z--Q (I) or a pharmaceutically acceptable salt thereof, wherein, X is selected from ##STR1## Y is selected from ##STR2## Z is ##STR3## and Q is ##STR4## or pharmaceutically-acceptable salts thereof, useful in the treatment of gastrointestinal disorders (including gallbladder disorders), central nervous system disorders, insulin-related disorders and pain, as well as in appetite regulation.

  公式（I）的选择性和有效的Type-A CCK受体激动剂为：X--Y--Z--Q（I）或其药学上可接受的盐，其中，X选自##STR1##，Y选自##STR2##，Z为##STR3##，Q为##STR4##或其药学上可接受的盐，可用于治疗胃肠道疾病（包括胆囊疾病）、中枢神经系统疾病、胰岛素相关疾病和疼痛，以及食欲调节。
• Synthesis and biological activity of angiotensin II analog containing a Val-His replacement, Val.psi.[CH(CONH2)HN]His
  作者：Raju Mohan、Yuo Ling Chou、Ron Bihovsky、William C. Lumma、Paul W. Erhardt、Kenneth J. Shaw

  DOI：10.1021/jm00112a014

  日期：1991.8

  The dipeptide mimic Val psi[CH(CONH2)NH]His (4) was incorporated into angiotensin II (AII) analogues to provide an octapeptide saralasin derivative (29) as well as tetrapeptide analogue 19. Three C-terminal tetrapeptides (21, 25, and 28) were also prepared. All compounds were tested for their ability to displace 3H-AII from rabbit adrenal gland homogenate and as antagonists of AII and AI on guinea

  将二肽模拟物Val psi [CH（CONH2）NH] His（4）掺入血管紧张素II（AII）类似物中，以提供八肽aralasin衍生物（29）以及四肽类似物19。三个C端四肽（21，25 （和28）也已准备好。测试了所有化合物从兔肾上腺匀浆中置换3H-AII的能力以及在豚鼠回肠上作为AII和AI的拮抗剂的能力。八肽类似物29的活性比亲本肽30低700倍。所有C末端片段19、21、25和28均没有可测量的AII拮抗剂活性。在四个四肽片段中，只有21个显示出任何明显的结合活性。
• Polyalkylene Polymer Compounds and Uses Thereof
  申请人：Biogen Idec MA Inc.

  公开号：US20150132259A1

  公开（公告）日：2015-05-14

  The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.

  本发明涉及新型聚烯基醇化合物及其使用方法。特别是，包含新型聚乙烯醇共轭物的化合物被单独使用或与抗病毒药物结合治疗病毒感染，例如慢性丙型肝炎。
• POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF
  申请人：Lin KoChung

  公开号：US20120014916A1

  公开（公告）日：2012-01-19

  The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.

  本发明涉及新型聚烯烃醚化合物及其使用方法。具体而言，包括一种新型聚乙烯醇共轭物的化合物，可单独或与抗病毒药物联合使用，用于治疗病毒感染，如慢性丙型肝炎。
• Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N.epsilon.)-amide residues
  作者：Kazumi Shiosaki、Chun Wel Lin、Hana Kopecka、Richard A. Craig、Bruce R. Bianchi、Thomas R. Miller、David G. Witte、Michael Stashko、Alex M. Nadzan

  DOI：10.1021/jm00089a010

  日期：1992.5

  A series of Boc-CCK-4 derivatives represented by the general structure Boc-Trp-Lys(N(epsilon)-COR)-Asp-Phe-NH2, where R is an aromatic, heterocyclic, or aliphatic group, are potent and selective CCK-AT receptor agonists. These amide-bearing compounds complement the previously described urea-based tetrapeptides (Shiosaki et al. J. Med. Chem. 1991, 34, 2837-2842); structure-activity studies revealed parallel as well as divergent trends between these two series. A significant correlation was observed between pancreatic binding affinity and the resonance constant R of the phenyl substituent in one particular series of derivatives. Sulfation of phenolic amides appended onto the epsilon-amino group of the lysine did not affect affinity for the CCK-AT receptor in contrast to the 500-fold increase in binding potency observed upon sulfation of CCK-8, suggesting that the lysine appendage and the sulfated tyrosine in CCK-8, both key structural elements that impart high affinity for the CCK-A receptor, are interacting differently with the receptor. The amide-bearing tetrapeptides are full agonists relative to CCK-8 in stimulating pancreatic amylase release while being partial agonists in eliciting phosphoinositide (PI) hydrolysis. Both effects were blocked by selective CCK-A receptor antagonists.